Many COVID-19 patients with acute hypoxemic respiratory failure may require invasive mechanical ventilation [1]. However, deciding whether and when a patient should be intubated is complex, especially in COVID-19 patients who commonly exhibit severe hypoxemia without clinical signs of respiratory failure (the so-called silent hypoxemia) [2]. While clinical signs of respiratory failure seem to be universally acknowledged as intubation criteria [3], their precise definition is lacking. Some authors have consequently used definite thresholds to guide intubation [4], but this approach is debated [5] as an individualized strategy may be more adequate. In our ICU, only COVID-19 patients showing persistent signs of respiratory distress associated with profound hypoxemia were intubated.
We therefore aimed (1) to assess the proportion of our COVID-19 patients not receiving invasive mechanical ventilation despite high levels of supplemental oxygen (≥ 15L/min for ≥ 6 h) as well as (2) to describe their clinical and biological features on the day of worst clinical status.
We retrospectively analyzed data of COVID-19 patients (positive SARS-COV-2 RT-PCR) with acute respiratory failure admitted to our hospital between March 1st, 2020 and March 1st, 2021.
Patients were included if (1) they received 15 or more L/min of supplemental oxygen for ≥ 6 h while being hospitalized either in the wards or in ICU and if (2) they did not undergo tracheal intubation except for hypoxic cardiac arrest occurring while breathing spontaneously. Patients with a “do-not-intubate” order or still hospitalized were excluded.
Baseline was defined as the day patients met the inclusion criteria. The day of worst clinical status was defined as the day they received the highest oxygen flow with the highest respiratory rate (RR).
Among 161 patients without a “do-not-intubate” order, 49 (30%, 95% confidence interval 23–38%) did not receive invasive mechanical ventilation (Fig. 1). Baseline characteristics and description of the patients on the day of worst clinical status (number of days after hospital admission: 3 [4–6]) are detailed in Table 1. On the day of worst clinical status, the proportion of patients treated with non-invasive ventilation, high-flow nasal cannula and standard oxygen therapy was 8, 39 and 61%, respectively. The highest RR was 36 [28–40]/min while lowest SpO2 and PaO2 were 91 [90–92] % and 65 [54–73] mmHg, respectively. Fifteen patients (31%) had a RR ≥ 40/min. Median PaCO2 was 37 [34–42] mmHg and lactate was 1.7 [1.3–1.9] mmol/L.
Fig. 1.
Flowchart
Table 1.
Characteristics at baseline and on the day of worst clinical status of 49 non-intubated COVID-19 patients with acute respiratory failure hospitalized in the ICU (n = 22) or in the wards (n = 27)
Total | Patients hospitalized in ICU | Patients hospitalized in the wards | |
---|---|---|---|
n = 49 | n = 22 | n = 27 | |
Baseline* characteristics | |||
Age (years) | 60 [50–66] | 63 [58–67] | 55 [46–63] |
Male | 40 (82%) | 17 (78%) | 23 (85%) |
Diabetes | 15 (31%) | 9 (41%) | 6 (22%) |
Obesity (BMI > 30 kg/m2) | 16 (33%) | 10 (46%) | 6 (22%) |
Hypertension | 18 (37%) | 10 (46%) | 8 (30%) |
Chronic heart failure or coronary artery disease | 3 (6%) | 3 (14%) | 0 (0%) |
Immunosuppression | 5 (10%) | 3 (14%) | 2 (7%) |
Charlson comorbidity index | 2 [1–3] | 3 [1–4] | 2 [0–3] |
SAPS II | 27 [24–30] | 28 [24–30] | 27 [22–30] |
Days from hospital admission to baseline | 3 [1–4] | 2 [1–4] | 3 [2–5] |
Days from symptoms onset to baseline | 9 [7–11] | 9 [8–11] | 9 [7–11] |
Dexamethasone therapy | 35 (71%) | 16 (73%) | 19 (70%) |
Antibiotic therapy | 30 (61%) | 10 (46%) | 20 (74%) |
Clinical features on the day of worst clinical status | |||
Standard oxygen therapy | 30 (61%) | 4 (18%) | 26 (96%) |
Maximum oxygen flow (liters per min) | 15 [15–15] | 20 [15–29] | 15 [15–15] |
High-flow nasal cannula | 19 (39%) | 18 (82%) | 1 (4%) |
Maximum FiO2 | 1 [1–1] | 1 [1–1] | 1 |
Non-invasive ventilation | 4 (8%) | 4 (18%) | 0 (0%) |
Maximum FiO2 | 1 [1–1] | 1 [1–1] | – |
Highest respiratory rate (/min) | 36 [28–40] | 38 [35–46] | 32 [28–37] |
Lowest SpO2 (%) | 91 [90–92] | 90 [86–91] | 91 [91–94] |
Lowest mean arterial pressure (mmHg) | 90 [82–98] | 91 [83–100] | 89 [82–96] |
Highest heart rate (/min) | 92 [80–104] | 94 [82–108] | 90 [80–98] |
Highest temperature (°C) | 37.7 [37–38.7] | 38.0 [37–38.8] | 37.5 [37–38.2] |
Biological data on the day of worst clinical status | |||
Leucocytes (/mm3) | 10,150 [8175–12975] | 11,150 [9150–13875] | 8850 [6600–10475] |
C-reactive protein (mg/L) | 119 [34–180] | 149 [49–296] | 115 [23–154] |
pH | 7.46 [7.44–7.48] | 7.47 [7.43–7.48] | 7.45 [7.44–7.45] |
PaO2 (mmHg) | 65 [54–73] | 61 [52–69] | 68 [65–102] |
PaCO2 (mmHg) | 37 [34–42] | 36 [33–40] | 40 [38–44] |
Arterial lactate (mmol/l) | 1.7 [1.3–1.9] | 1.7 [1.3–2.0] | 1.4 [0.9–1.7] |
Creatininemia (μmol/L) | 65 [57–80] | 63 [56–80] | 66 [57–79] |
Outcomes | |||
Hypoxic cardiac arrest | 1 (2%) | 1 (5%) | 0 (0%) |
Hospital mortality | 1 (2%) | 1 (5%) | 0 (0%) |
Duration of high flow oxygen administration** (h) | 82 [45–124] | 114 [58–145] | 72 [48–122] |
Discharged home with oxygen therapy | 18 (37%) | 5 (23%) | 13 (48%) |
Continuous variables are reported as medians [quartile 1–quartile 3] and categorical variables are reported as numbers (percentages)
*Baseline was defined as the day patients met the inclusion criteria i.e. received 15 or more L/min of supplemental oxygen for ≥ 6 h
**High flow oxygen administration was defined as standard oxygen therapy with a flow of 15 L/min or more, or high-flow nasal cannula with FiO2 of 0.80 or more
On the day of worst clinical status, only 22 (45%) were hospitalized in ICU (Fig. 1). One of them presented hypoxic cardiac arrest while switching from high-flow nasal cannula to noninvasive ventilation.
Among the 27 (55%) patients managed in the wards, one (4%) was treated with high-flow nasal cannula while 26 (96%) were treated with standard oxygen therapy alone, with a highest oxygen flow of 15 [15–15] L/min, a highest RR of 32 [28–37]/min and a lowest SpO2 of 91 [91–94]%.
We herein report that 30% of our patients receiving ≥ 15L/min oxygen flow did not receive invasive mechanical ventilation despite significant tachypnea. Noteworthy, more than half of them were managed outside the ICU without hypoxic cardiac arrest, which could be of interest in a context of a massive inflow of critically ill COVID-19 patients.
Despite one hypoxic cardiac arrest (occurring in a patient cared for in the ICU), avoiding intubation might be feasible in some patients with high levels of supplemental oxygen and significant tachypnea. Rather than predefined SpO2 or RR thresholds, clinical acumen appears of paramount importance when deciding to initiate invasive mechanical ventilation.
Our results cannot be generalized to other centers nor to any other respiratory diseases than COVID-19. However, this study strengthens the idea that managing non-intubated patients with respiratory failure is a “clinical art” and that individualized patient care is necessary [6].
Acknowledgements
We warmly acknowledge Dr Elsa Logre, Dr Olivier Pajot, Dr Jo-Anna Tirolien, Dr Olivia Picq, Dr Florence Sarfati, Dr Paul Desaint, and all the residents who took care of the patients as well as Dr Clara Finck for her writing assistance.
Abbreviations
- BMI
Body mass index
- SAPS II
Simplified acute physiology score
- ICU
Intensive care unit
Authors' contributions
SC, GP, RC and DC are responsible for the conception and design. All the authors took care of the patients. SC is responsible for data acquisition. All the authors were responsible for analysis and interpretation of data. All authors read and approved the final manuscript.
Funding
No funding.
Availability of data and materials
The dataset used and analyzed for the current study is available from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
Not applicable for a retrospective monocenter observational study. This non-interventional data-based research used the care data collected during patient hospital stay. There is no processing of indirectly identifiable data. Patients and proxies were informed, and written consent was waived.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47:60–73. [DOI] [PMC free article] [PubMed]
- 2.Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202:356–360. doi: 10.1164/rccm.202006-2157CP. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Azoulay E, de Waele J, Ferrer R, Staudinger T, Borkowska M, Povoa P, et al. International variation in the management of severe COVID-19 patients. Crit Care. 2020;24:486. doi: 10.1186/s13054-020-03194-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, Llontop C, Guerder A, Trosini-Desert V, et al. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study. Eur Respir J. 2020;56:2001692. [DOI] [PMC free article] [PubMed]
- 5.Tobin MJ, Laghi F, Jubran A. Caution about early intubation and mechanical ventilation in COVID-19. Ann Intensive Care. 2020;10:78. doi: 10.1186/s13613-020-00692-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tobin MJ, Jubran A, Laghi F. Noninvasive strategies in COVID-19: epistemology, randomised trials, guidelines, physiology. Eur Respir J. 2021;57:2004247. doi: 10.1183/13993003.04247-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The dataset used and analyzed for the current study is available from the corresponding author on reasonable request.